Clomipramine Impurities

Clomipramine is a tricyclic antidepressant (TCA) that primarily exerts therapeutic effects through potent serotonin reuptake inhibition. This medication is FDA-approved to treat obsessive-compulsive disorder (OCD) in patients aged 10 and older. Pharmacologically, clomipramine displays high affinity for the serotonin transporter SERT with weaker inhibition of the norepinephrine transporter NET, and it also interacts with muscarinic, histamine H1, and alpha-1 adrenergic receptors, which contributes to its anticholinergic, sedative, and orthostatic effects. The principal active metabolite is N-desmethylclomipramine, formed by hepatic N-demethylation via cytochrome P450 enzymes including CYP2D6, and both parent and metabolite are subject to enterohepatic considerations and variable clearance in poor CYP2D6 metabolizers. Typical clinical properties include moderate to high oral bioavailability, substantial plasma protein binding, and a multiday effective half-life when steady state is reached. Monitoring considerations include baseline and periodic assessment of cardiac conduction in patients with risk factors, evaluation for anticholinergic adverse effects, and attention to drug interactions that inhibit CYP2D6 or prolong cardiac conduction.